Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Microbiol Res ; 286: 127812, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38954992

RESUMO

Clostridioides difficile infection (CDI) poses a significant health threat due to high recurrence rates. Antimicrobial agents are commonly used to manage CDI-related diarrhoea; however, by aggravating intestinal dysbiosis, antibiotics enable C. difficile spores germination and production of toxins, the main virulence factors. Therefore, the binding of exotoxins using adsorbents represents an attractive alternative medication for the prevention and treatment of relapses. In this study, we provided evidence that the natural insoluble polysaccharides, named ABR119, extracted by plant cell cultures, effectively trap C. difficile toxins. In our experiments, ABR119 exhibited no cytotoxicity in vitro and was safely administered in vivo. In the animal model of C. difficile-associated colitis, ABR119 (50 mg/kg body weight) significantly reduced the colonic myeloperoxidase activity and severity of inflammation, preventing body weight loss. These effects were not evident when we treated animals with wheat bran polysaccharides. We did not detect bacterial killing effects of ABR119 against C. difficile nor against bacterial species of the normal gut microbiota. Moreover, ABR119 did not interfere in vitro with the antimicrobial activities of most clinically used antibiotics. In summary, ABR119 holds promise for treating and preventing C. difficile colitis by trapping the bacterial toxins, warranting further studies to assess the ABR119 potential in human infections caused by C. difficile.


Assuntos
Antibacterianos , Toxinas Bacterianas , Clostridioides difficile , Infecções por Clostridium , Colite , Modelos Animais de Doenças , Polissacarídeos , Polissacarídeos/farmacologia , Polissacarídeos/metabolismo , Clostridioides difficile/efeitos dos fármacos , Clostridioides difficile/patogenicidade , Animais , Colite/microbiologia , Colite/tratamento farmacológico , Colite/prevenção & controle , Colite/induzido quimicamente , Infecções por Clostridium/prevenção & controle , Infecções por Clostridium/microbiologia , Infecções por Clostridium/tratamento farmacológico , Toxinas Bacterianas/metabolismo , Antibacterianos/farmacologia , Humanos , Células Vegetais , Camundongos , Colo/microbiologia , Colo/efeitos dos fármacos , Microbioma Gastrointestinal/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA